Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aristeromycin SCHEMBL10353292 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12280589 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL10353291 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL14515457 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL29695815 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12173988 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL7534801 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL9820408 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL692209 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL15297972 | 0.99 | AHCY (0.97) | AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145581-A1 | COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | HONG GUAN, LTD. (CN) | 2016-05-26 | — | — | US | disclosed |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | ZHONG MINGHONG (US) | 2015-09-24 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
| US-7220870-B2 | Hydrolytic kinetic resolution of cyclic substrates | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145581-A1 | COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | AHCY, GSKIP, AHCYL1 | AHCY 1/4885ADORA2B 1029/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | AHCY 4122/4885ADORA2B 388/4885 |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | TYMP, ENPP3, PNP | AHCY 3087/4885ADORA2B 147/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | AHCY 3828/4885ADORA2B 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.